Development and characterization of atorvastatin calcium loaded chitosan nanoparticles for sustain drug delivery

Advanced Materials Letters

Volumn 3, Issue 6, 2012, Pages 466-470

  Bathoo, Afifa ^a   Vishakante, Gowda D ^a   Khan, Mohammed S ^a   Shivakumar, H G ^a  

^a JSS COLLEGE OF PHARMACY   (India)

Author keywords

Atorvastatin calcium; Chitosan; Nanoparticles; Solvent evaporation

Indexed keywords

EID: 84873827585     PISSN: 09763961     EISSN: 0976397X     Source Type: Journal    
DOI: 10.5185/amlett.2012.icnano.153     Document Type: Article

References (15)

1. Arunkumar N, Deecaraman M, Rani C, Mohanraj KP, Venkates KK. Preparation and solid state characterization of atorvastatin nanosuspensions for enhanced solubility and dissolution. Int.J. PharmTech Res.2009,1(4).
2. Choi, W.S., Kim, H.I., Kwak, S.S., Chung, H.Y., Chung, H.Y., Yamamoto, K., Oguchi, T., Tozuka, Y., Yonemochi, E., Terada, K. Amorphous ultrafine particle preparation for improvement of bioavailability of insoluble drugs: grinding characteristics of fine grinding mills. Int. J. Miner. Process. 2004, 74, S165-S172.
3. Paradkar, A., Ambike, A., Jadhav, B., Mahadik, K. Characterization of curcumin-PVP solid dispersion obtained by spray drying. Int. J. Pharm., 2004, 271, 281- 286.
4. Chen, Y., Zhang, G., Neilly, J., Marsh, K., Mawhinney, D., Sanzgiri, Y. Enhancing the bioavailability of ABT-963 using solid dispersion containing Pluronic F-68. Int. J. Pharm., 2004, 286, 69- 80.
5. Jun, S., Kim, M., Kim, J., Park, H., Lee, S., Woo, J., Hwang, S. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. Eur. J. Pharm. Biopharm., 2007, 66, 413-421.
6. Kim,M.-S., Lee, S., Park, J.-S.,Woo, J.-S., Hwang, S.-J. Micronization of cilostazol using supercritical antisolvent (SAS) process: effect of process parameters.Powder Technol., 2007, 177, 64-70.
7. Mohanraj VJ & Chen Y. Nanoparticles - A Review. Tropical Journal of Pharmaceutical Research, June 2006; 5 (1): 561-573.
8. Sailaja AK, Amareshwar P, Chakravarty P. Chitosan nanoparticles as a drug delivery system. July - September 2010 RJPBCS Volume 1 Issue 3 Page No. 474.
9. López-León T, Carvalho ELS, Seijo B, Ortega-Vinuesa JL, Bastos-González D. Physicochemical characterization of chitosan nanoparticles: electrokinetic and stability behaviour. Journal of Colloid and Interface Science 283 (2005) 344-351.
10. Hoppe-Seiler F. Ber Dtsch Chem Ges. 1994; 27:3329-3331.
11. Roberts GAF. Solubility and solution behaviour of chitin and chitosan. In: Roberts GAF, ed. Chitin Chemistry. MacMillan, Houndmills. 1992:274-329.
12. Min-Soo Kim, Shun-Ji Jin, Jeong-Soo Kim, Hee Jun Park, Ha-Seung Song, Reinhard H.H. Neubert, Sung-Joo Hwang. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. European Journal of Pharmaceutics and Biopharmaceutics 69 (2008) 454-465.
13. Lennernas, H. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet., 2003, 42, 1141-1160.
14. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F, New insights into the pharmacodynamic and pharmacokinetic properties of statins, Pharmcol. Ther. 84 (1999) 413-428.
15. Cilla DD, Whitfield JLR, Gibson DM, Sedman AJ, Posvar EL. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects, Clin. Pharmacol. Ther. 60 (1996) 687-695.